Benjamin H. Lowentritt, MD, FACS, Discusses How 18F-rhPSMA-7.3 PET Expands the Armamentarium for Suspected Recurrent Prostate Cancer

Novel PSMA-targeting PET ligand 18F-rhPSMA-7.3 adds to the recurrent prostate cancer armamentarium, according to Benjamin H. Lowentritt, MD, FACS.

During the 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting, Benjamin H. Lowentritt, MD, FACS, director of Minimally Invasive Surgery and Robotics; director of the Prostate Cancer Care Program, Chesapeake Urology, Baltimore, Maryland; and president of the American Urological Association, MidAtlantic Region, spoke with CancerNetwork® about how an analysis of the phase 3 SPOTLIGHT study (NCT04186845), assessing 18F-rhPSMA-7.3 in subgroups of patients with suspected recurrent prostate cancer, adds to the existing diagnostic tools for this patient population.


The great part about the SPOTLIGHT study is that it’s adding to the armamentarium that we have for diagnosis and eventually treatment of prostate cancer. [18F-rhPSMA-7.3] is an agent that seems to have the potential for less bladder uptake; it’s a little bit less excreted in the urine and accumulates less in the bladder. The hope would be that it would allow for a very clear picture within the bladder when there’s something to be found there. It continues to add to the options that we have and the hope that this will be available clinically in the future. It’s very promising to have more and more options.


Lowentritt, B. Impact of Clinical factors on 18F-rhPSMA-7.3 detection rates in men with recurrent prostate cancer: findings from the phase 3 SPOTLIGHT study. Presented at 2022 American Society for Radiation Oncology Annual Meeting (ASTRO); October 23-26, 2022; San Antonio, TX. Abstract 1049. Accessed November 3, 2022.

Related Videos
Early data from ongoing clinical trials suggest the potential safety and efficacy of novel radium-223 combinations as treatment for metastatic castration-resistant prostate cancer.
An expert from Dana-Farber Cancer Institute discusses findings from the final overall survival analysis of the phase 3 ENGOT-OV16/NOVA trial.
The use of palliative care in ovarian cancer resulted in a decrease in overall readmissions and index hospitalization costs.
Current clinical trials look to assess 177Lu-PSMA-617 in combination with other therapies including androgen deprivation therapy and docetaxel.
An expert from Dana-Farber Cancer Institute indicates that patients with prostate cancer who have 1 risk factor should undergo salvage radiotherapy following radical prostatectomy before their prostate-specific antigen level rises above 0.25 ng/ml.
An expert from Weill Cornell Medicine highlights key clinical data indicating the benefits of radium-223 in the treatment of patients with metastatic castration-resistant prostate cancer.
The risk of radionuclide exposure to the public reflects one reason urologists need to collaborate with radiation oncologists when administering radiopharmaceuticals to patients with prostate cancer.
Switching out beta emitters for alpha emitters, including radium-223, is one way to improve radiopharmaceutical treatment of prostate cancer, according to an expert from Weill Cornell Medicine.
Data demonstrate the feasibility of automated glomerular filtration rate prediction to decide between partial nephrectomy and radical nephrectomy in kidney cancer, according to an expert from the Cleveland Clinic.
Early phase trials investigating cellular therapies, bispecific antibodies, and antibody-drug conjugates for refractory kidney cancer may uncover strategies to overcome resistance mechanisms.
Related Content